Novartis petitions FDA on biosimilar naming convention

01-11-2013

Novartis petitions FDA on biosimilar naming convention

Image: Novartis AG

Novartis has urged the US Food and Drug Administration (FDA) to allow biosimilars to bear the same international nonproprietary names (INNs) as their reference products.


Novartis, Sandoz, FDA, biosimilars, INNs

LSIPR